title: Extended-release albuterol in the treatment of 6- to 12-year-old asthmatic children.
abstract: BACKGROUND
  Albuterol sulfate, in the syrup and tablet form for oral administration, has been an effective treatment for adults and children with bronchial asthma. Extended-release albuterol sulfate tablets (Proventil Repetabs, Schering Corp.) provide a convenient, twice-daily dosing regimen, but are indicated only for patients > or = 12 years of age.
  
  
  OBJECTIVE
  This study was undertaken to determine whether patients 6 to 12 years of age could be effectively and safely treated with extended-release albuterol tablets.
  
  
  METHODS
  This was a randomized, double-blind, placebo-controlled, parallel group study of 157 patients in five centers. Patients were randomized to 4 weeks' treatment with extended-release albuterol tablets, 4 mg twice daily (q 12h), increasing up to 12 mg q 12h, or placebo. Efficacy was evaluated based on pulmonary function tests (PFTs), physician and patient evaluations, and data collected from patients' diaries on PEFR, asthma symptoms, number of nighttime awakenings, and number of tablets taken. The primary efficacy parameter was area under the curve (AUC) for FEV1, evaluated for 8 to 12 hours post-dosing. Safety was evaluated based on vital signs, electrocardiograms, and adverse events.
  
  
  RESULTS
  Mean AUCs for FEV1 were significantly greater in the albuterol group at days 1 and 8 (P < or = .03). The albuterol group showed consistently lower severity scores for asthma symptoms. Physicians' and patients' global evaluations favored the albuterol group over the placebo group. No serious, treatment-related adverse events were reported. There were no clinically meaningful changes from baseline in either treatment group for vital signs or electrocardiograms.
  
  
  CONCLUSIONS
  Extended-release albuterol tablets (4 mg), administered to children 6 to 12 years old in divided doses of up to 24 mg/day, improved pulmonary function and asthmatic symptoms and were well tolerated.
authors.affiliation: Children's Hospital of Pittsburgh, Pennsylvania, USA.
authors.forename: D P
authors.initials: DP
authors.lastname: Skoner
authors.forename: H
authors.initials: H
authors.lastname: Boltansky
authors.forename: R H
authors.initials: RH
authors.lastname: Kobayashi
authors.forename: D S
authors.initials: DS
authors.lastname: Pearlman
authors.forename: G
authors.initials: G
authors.lastname: Shapiro
authors.forename: J E
authors.initials: JE
authors.lastname: Harrison
authors.forename: L M
authors.initials: LM
authors.lastname: Trochelmann
authors.forename: R R
authors.initials: RR
authors.lastname: Lorber
mesh_terms: D000293:Adolescent; D000420:Albuterol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D012129:Respiratory Function Tests
chemical_list: D003692:Delayed-Action Preparations; D000420:Albuterol